Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: A prospective, observational study

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 2, 2009, Pages 374-379

  Guaraldi, Giovanni ^a   Roverato, Alberto ^b   Giovanardi, Chiara ^a   Ravera, Federica ^a   Squillace, Nicola ^a   Orlando, Gabriella ^a   Cappelli, Gianni ^a   Esposito, Roberto ^a   Palella, Frank ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AIDS; Drug toxicity; MDRD; Renal insufficiency

Indexed keywords

CREATINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; VIRUS LOAD;

ADENINE; ADULT; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 58849095000     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn499     Document Type: Article

References (26)

1. Szczech LA, Gange SJ, van der Horst C et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61: 195-202.
2. Gupta SK, Mamlin BW, Johnson CS et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004; 61: 1-6.
3. Gardner LI, Holmberg SD, Williamson JM et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 203-9.
4. Szczech LA, Hoover DR, Feldman JG et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-206.
5. Carbone L, D'Agati V, Cheng JT et al. Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med 1989; 87: 389-95.
6. D'Agati V, Suh JI, Carbone L et al. Pathology of HIV-associated nephropathy: A detailed morphologic and comparative study. Kidney Int 1989; 35: 1358-70.
7. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis 2002; 40: 1331-3.
8. Creput C, Gonzalez-Canali G, Hill G et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17 935-7.
9. Schaaf B, Aries SP, Kramme E et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: E41-3.
10. Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephro-toxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-3.
11. Peyriere H, Reynes J, Rouanet I et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269-73.
12. Coca S, Perazella MA. Rapid communication: Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-4.
13. Gaspar G, Monereo A, Garcia-Reyne A et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: A call for caution. AIDS 2004; 18: 351-2.
14. Lundgren JD, Battegay M, Behrens G et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9: 72-81.
15. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-85.
16. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
17. Squires K, Pozniak AL, Pierone G Jr et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med 2003; 139: 313-20.
18. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-63.
19. Izzedine H, Isnard-Bagnis C, Hulot JS et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18 1074-6.
20. Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr 2004; 37: 1489-95.
21. Antoniou T, Raboud J, Chirhin S et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: A retrospective cohort study. HIV Med 2005; 6: 284-90.
22. Winston A, Amin J, Mallon P et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006; 7: 105-11.
23. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 93-5.
24. Julg BD, Bogner JR, Crispin A et al. Progression of renal impairment under therapy with tenofovir. AIDS 2005; 19: 1332-3.
25. El Sahly HM, Teeter L, Zerai T et al. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. AIDS 2006; 20 786-7.
26. Reid A, Stöhr W, Walker AS et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46: 1271-81.